Andrew Sinclair - Jun 8, 2021 Form 4 Insider Report for Sierra Oncology, Inc. (SRRA)

Role
Director
Signature
/s/ Andrew Sinclair; By: Mary Christina Thomson, Attorney-In-Fact
Stock symbol
SRRA
Transactions as of
Jun 8, 2021
Transactions value $
$0
Form type
4
Date filed
6/9/2021, 10:24 AM
Previous filing
Jun 4, 2021
Next filing
Aug 10, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (Right To Buy) Award $0 +6K $0.00 6K Jun 8, 2021 Common Stock 6K $18.11 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Option fully vests and becomes exercisable on June 8, 2022, subject to the Reporting Person's provision of service to the Issuer as of the vesting date.
F2 The Reporting Person is a Partner of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VII, LP ("ABV VII"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VII, and must exercise the Option solely upon the direction of ALLP.
F3 ABV VII may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VII. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VII or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.